PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

BACKGROUND: Despite the availability of effective drug therapies that reduce low‐density lipoprotein (LDL)‐cholesterol (LDL‐C), cardiovascular disease (CVD) remains an important cause of mortality and morbidity. Therefore, additional LDL‐C reduction may be warranted, especially for patients who are...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cochrane Database Syst Rev
Autors principals: Schmidt, Amand F, Pearce, Lucy S, Wilkins, John T, Overington, John P, Hingorani, Aroon D, Casas, Juan P
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Ltd 2017
Matèries:
Medicine General & Introductory Medical Sciences
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6478267/
https://ncbi.nlm.nih.gov/pubmed/28453187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD011748.pub2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars